Here's Why Jiangsu Recbio Technology (HKG:2179) Can Afford Some Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. We note that Jiangsu Recbio Technology Co., Ltd. (HKG:2179) does have debt on its balance sheet. But is this debt a concern to shareholders?

Our free stock report includes 3 warning signs investors should be aware of before investing in Jiangsu Recbio Technology. Read for free now.

What Risk Does Debt Bring?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, plenty of companies use debt to fund growth, without any negative consequences. When we examine debt levels, we first consider both cash and debt levels, together.

What Is Jiangsu Recbio Technology's Net Debt?

As you can see below, at the end of December 2024, Jiangsu Recbio Technology had CN¥878.3m of debt, up from CN¥631.6m a year ago. Click the image for more detail. However, it also had CN¥450.3m in cash, and so its net debt is CN¥427.9m.

How Strong Is Jiangsu Recbio Technology's Balance Sheet?

The latest balance sheet data shows that Jiangsu Recbio Technology had liabilities of CN¥839.4m due within a year, and liabilities of CN¥571.5m falling due after that. On the other hand, it had cash of CN¥450.3m and CN¥93.9m worth of receivables due within a year. So its liabilities outweigh the sum of its cash and (near-term) receivables by CN¥866.7m.

This deficit isn't so bad because Jiangsu Recbio Technology is worth CN¥3.40b, and thus could probably raise enough capital to shore up its balance sheet, if the need arose. But we definitely want to keep our eyes open to indications that its debt is bringing too much risk. There's no doubt that we learn most about debt from the balance sheet. But you can't view debt in total isolation; since Jiangsu Recbio Technology will need earnings to service that debt. So if you're keen to discover more about its earnings, it might be worth checking out this graph of its long term earnings trend.

See our latest analysis for Jiangsu Recbio Technology

Given its lack of meaningful operating revenue, Jiangsu Recbio Technology shareholders no doubt hope it can fund itself until it has a profitable product.

Caveat Emptor

Not only did Jiangsu Recbio Technology's revenue slip over the last twelve months, but it also produced negative earnings before interest and tax (EBIT). Indeed, it lost a very considerable CN¥572m at the EBIT level. Considering that alongside the liabilities mentioned above does not give us much confidence that company should be using so much debt. So we think its balance sheet is a little strained, though not beyond repair. However, it doesn't help that it burned through CN¥637m of cash over the last year. So in short it's a really risky stock. There's no doubt that we learn most about debt from the balance sheet. However, not all investment risk resides within the balance sheet - far from it. These risks can be hard to spot. Every company has them, and we've spotted 3 warning signs for Jiangsu Recbio Technology (of which 2 shouldn't be ignored!) you should know about.

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.